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ABSTRACT
Serum levels of IgG, IgM and IgA against severe acute respiratory distress syndrome (SARS)-associated
coronavirus (SARS-CoV) were detected serially with the use of immunofluorescent antibody assays in
30 patients with SARS. Seroconversion for IgG (mean 10 days) occurred simultaneously, or 1 day earlier,
than that for IgM and IgA (mean 11 days for both). IgG could be detected as early as 4 days after the
onset of illness. The earliest time at which these three antibodies reached peak levels was similar (mean
15 days). A high IgG level (1:800) could persist for > 3 months. The kinetics of neutralisation antibodies
obtained with 100· the tissue culture infective dose (TCID50) of the SARS-CoV TW1 strain in five
patients with SARS nearly paralleled those for IgG. There were no significant differences in the kinetics
of the IgG, IgM and IgA responses between patients with or without underlying medical disease, steroid
or intravenous immunoglobulin therapy, or mechanical ventilation.
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INTRODUCTION
Severe acute respiratory distress syndrome
(SARS) is an emerging infection that has affected
more than 8000 patients in many countries [1].
This highly contagious infection has a propensity
to spread to healthcare workers and household
members, and may also cause outbreaks in the
community [2–7]. As of 5 July 2003, when Taiwan
was declared free of SARS by the World Health
Organization, 346 laboratory-confirmed SARS
cases had been reported, and 37 (11%) of these
patients had died [1].
The first SARS patient in Taiwan was identified
in the National Taiwan University Hospital
(NTUH) on 25 February 2003, and 76 patients
with SARS were eventually identified in this
hospital during the outbreak [2,7–9]. Among these
patients, 18 had microbiological evidence of
infection with SARS-associated coronavirus
(SARS-CoV), including positive RT-PCR and
real-time RT-PCR assays from respiratory or
serum samples. In all patients, an indirect
enzyme-linked immunosorbent assay (ELISA)
revealed IgG antibody against SARS-CoV in
serum samples collected 28–35 days after the
onset of fever.
The aim of this study was to evaluate the
chronological evolution of IgM, IgA, IgG and
neutralisation (NT) antibodies following SARS-
CoV infection of 30 patients who were treated at
NTUH during the epidemic.
PATIENTS AND METHODS
Patients
Of the 76 SARS patients for whom serial serum samples
were preserved, 30 were included in this study. Sera from
these 30 patients (6–12 samples from each patient) were
collected from <7 days to 2–3 months after the onset of
illness (defined as first appearance of fever with body
temperature ‡ 38.3C). The patients were aged 25–80 years
(mean 43 years). Four patients had underlying disease,
namely diabetes mellitus (n = 2), hypertension (n = 1) and
chronic hepatitis B virus carriage (n = 1), while the other
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patients were previously healthy. Sputum or throat swab
specimens from 12 of these patients were positive for SARS-
CoV RNA.
Immunofluorescent antibody assays
Specific antibodies (IgG, IgM and IgA) to SARS-CoV were
determined with two different immunofluorescent antibody
(IFA) assays: an in-house assay using whole-cell lysate of
infected Vero E6 cells as an antigen, or a commercial kit (Anti-
SARS-CoV-IIFT; Euroimmun, Lu¨beck, Germany) [6,10]. For the
in-house IFA assay, spot slides were prepared by applying
10 lL of Vero E6 cell suspension, either infected or non-
infected with the SARS-CoV TW1 strain (GenBank accession
no. AY291451). Slides were dried and fixed in acetone. The
conjugates used were goat anti-human IgG, IgM and IgA
conjugated to fluorescein isothiocyanate (Organon Teknika-
Cappel, Turnhout, Belgium). The starting dilutions of serum
specimens were 1:25 for the in-house IFA and 1:10 for the
Euroimmun kit. Before determination of IgM and IgA anti-
bodies with IFA, IgG antibodies were removed from patient
sera by immunosorption with anti-human IgG, using either a
Eurosorb kit (Euroimmun) with the commercial IFA assay, or a
Gullsorb kit (Meridian Bioscience, Cincinnati, OH, USA) with
the in-house assay. The cut-off values for a positive result were
1:25 for the in-house IFA and 1:10 for the commercial IFA kit
[2,10].
ELISA
IgG antibody against SARS-CoV was also measured with an
indirect ELISA, with recombinant nucleocapsid as the coated
antigen (SARS-96 (TMB); General Biologicals, Hsin-Chu, Tai-
wan) [10,11]. The cut-off value for a positive IgG result by
ELISA was 0.26 [10,11].
Control sera
Controls comprised 200 paired sera from patients with
community-acquired pneumonia seen at NTUH from October
2001 to December 2002, 70 sera from hospitalised patients with
acute respiratory distress syndrome treated in 2002 at the
hospital, and ten sera from ten pregnant women obtained
during routine pre-labour check-ups in 2002. The control sera
were tested for the presence of IgG, IgM and IgA by the three
methods described above.
NT antibody assay
Briefly, sera from five patients were incubated at 56C for
30 min, and then diluted two-fold in cell culture medium
(modified Eagle medium). Aliquots (50 lL) of diluted sera
(from four-fold to 516-fold) were added to 50 lL of cell culture
medium containing 100· the tissue culture infective dose
(TCID50) of the SARS-CoV TW1 strain on a 96-well microtitre
plate and incubated at 37C for 2 h in CO2 5% v ⁄v. Finally,
100 lL of Vero E6 cells (2.5 · 105 ⁄mL) was added to each well
of the plate. The plates were incubated at 37C for 3–5 days in
CO2 5% v ⁄v and examined daily for a cytopathic effect. On
day 5, the highest dilution of serum that completely inhibited
100· TCID50 of SARS-CoV was recorded as the NT titre. NT
assays were performed in triplicate with negative control sera
from healthy volunteers.
RESULTS
All control sera were negative for IgG by ELISA,
and for IgG, IgM and IgA by IFA. The time
required for seroconversion, as determined by the
two IFA assays for IgG, IgM and IgA, and by the
two IFA assays and ELISA for IgG, was nearly
identical among these patients (Fig. 1). Tests for
IgG, IgM or IgA were negative until at least
3 days after the onset of illness in all 30 patients
(Fig. 1a). Assays for all three specific antibodies
were positive for at least 19 days1 after the onset of
illness in these patients. Seroconversion of IgG
(mean 10 days) occurred at the same time, or
1 day earlier, than for IgM and IgA (mean 11 days
for both). The time required for the first peak level
of these three antibodies was similar (mean
15 days) (Fig. 1b). The highest levels of IgG, IgM
and IgA were 1:6400, 1:640, and 1:1280, respect-
ively. All patients were positive for IgG for
> 28 days (1:400–1:1600), and one patient had a
high level of IgG (1:800) at 100 days2 after the
onset of illness. The levels of IgM and IgA started
to decline 3–4 weeks after the onset of illness, and
remained at low levels (1:40–1:80) at 12 weeks
after onset.
In addition to treatment with ribavirin (used for
29 of the 30 patients), 28 patients received intra-
venous methylprednisolone (1–11 days, mean
6 days, after the onset of illness, and 2–4 days
before any IgG response), 21 received intravenous
immunoglobulin (2–12 days, mean 6 days, after
the onset of illness), and nine were given mechan-
ical ventilation (4–12 days, mean 8 days, after the
onset of illness) following respiratory failure.
There were no significant differences in the
kinetics of the IgG, IgM and IgA response
between patients with or without underlying
medical disease, steroid or intravenous immuno-
globulin therapy, or mechanical ventilation.
However, two patients had early IgG seroconver-
sion (1:50 and 1:100, respectively) on day 4 of
illness before starting corticosteroid therapy (day
5), and one patient had IgG antibody (1:50) on day
5 of illness when corticosteroid therapy was
started.
NT antibody appeared on days 10–12 (mean
1:32), increased thereafter, and peaked (1:128–
1:256) on days 18–24. In four patients, the NT
antibody titre remained at 1:32 or 1:64 at 2 months
after onset, and was 1:64 on day 100 of the illness.
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Figs 2a and 2b illustrate the characteristic changes
in IgG, IgM, IgA and NT antibodies against SARS-
CoV in two previously healthy patients during
the acute and convalescent stages of the disease.
DISCUSSION
The results of this study demonstrate five import-
ant points. First, although previous reports have
indicated that specific IgG is not detected in SARS
patients until days 7–9 of the disease [2,11–16], the
present study showed clearly that IgG serocon-
version can start as early as 4 days after the onset
of illness. Second, in contrast to the profiles of
antibody responses against acute virus infections,
and a previous finding on humoral immunity
(IgG and IgM) to SARS [9], a simultaneous or
earlier IgG response against SARS-CoV TW1,
compared with IgM or IgA, was observed. This
indicates that detection of IgM or IgA would not
provide earlier evidence for SARS-CoV infection
than detection of IgG. Third, the study showed
the presence of low levels of IgM and IgA at
100 days after the onset of illness, although a
previous study showed the disappearance of IgM
after 12 weeks [14]. Fourth, the presence of
underlying disease (diabetes mellitus, hyperten-
sion, chronic hepatitis B virus carriage) and the
use of immunosuppressive or immunomodulato-
ry agents did not influence the dynamics of the
antibody response (i.e., the times required to
achieve seroconversion and peak antibody levels)
[2]. Finally, the presence of high levels of specific
IgG and NT antibodies to SARS-CoV in the late
convalescent stage (2 to at least 3 months3 after the
onset of illness) suggests that passive immunisa-
tion with convalescent plasma or concentrated
SARS-CoV IgG antibody from recovered SARS
patients might be an option for the treatment of
SARS.
The reason for a simultaneous or slightly earlier
IgG response is unclear. The time at which these
isotypes were detected might depend more on the
test employed than the actual timing of the IgM-
to-IgG switch. Theoretically, this should not
happen if these patients had a true primary
response to SARS, and should be accelerated if
it was a secondary response. One possibility is
that some patients were infected with SARS-CoV
before the documented febrile episodes during
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Fig. 1. Chronological evolution of IgG, IgM, and IgA
antibodies to SARS-associated coronavirus (SARS-CoV) in
30 patients with SARS. (a) Cumulative proportion against
time required for seroconversion to IgG, IgM and IgA
according to immunofluorescent antibody (IFA) assays. (b)
Cumulative proportion against time required for serocon-
version to IgG according to ELISA. (c) Cumulative propor-
tion against time required for peak levels of antibodies
according to IFA assays.
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the epidemic. This is difficult to exclude, but is
extremely unlikely. A previous study of emer-
gency room workers revealed a similar antibody
subclass response in two patients with mild
symptoms (fever with body temperature
< 38.3C) and one asymptomatic worker [10].
Alternatively, the observation could reflect the
low sensitivity of IFA assays for the detection of
IgM or IgA. It is known that detection of IgM or
IgA without the separation of IgG yields higher
rates of false-positive and false-negative results.
In the present study, IgG was absorbed before
detection of IgM and IgA in two different IFA
assays. Accordingly, the sensitivity of the IgM
and IgA assays after IgG absorption, rather than
the biology of the host response, might contribute
to this phenomenon. Therefore, the serological
response of SARS-CoV-infected patients might
need to be examined with the use of more
sensitive methods or different antigens.
Theoretically, steroids are more likely to inter-
fere with an established immune response than its
initiation4 , and the present study did not observe a
delay in the primary immune response with
steroid therapy. Previous observations have sug-
gested that the upsurge of IgG antibody to SARS-
CoV correlates with the clinical worsening of
pneumonia [2,7,14]. However, in the present
study, patients whose pulmonary condition im-
proved after corticosteroid therapy had similar
IgG profiles to patients who later developed
respiratory failure necessitating ventilator sup-
port. An over-exuberant host response, as well as
other immunopathological processes, might con-
tribute to a worsening of disease and progressive
lung damage.
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SARS patient who received corticosteroid, intravenous
immunoglobulin (IVIG) and mechanical ventilation. (b)
Antibody changes in a SARS patient who received corti-
costeroid therapy only.
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